Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
Arcus/Gilead Readout Expected Next
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.